Journal of diabetes and its complications最新文献

{"title":"Health status in stage B heart failure from diabetic cardiomyopathy baseline results from ARISE-HF","authors":"Tariq Jamal Siddiqi ,&nbsp;Yuxi Liu ,&nbsp;Faiez Zannad ,&nbsp;W.H. Wilson Tang ,&nbsp;Scott Solomon ,&nbsp;Julio Rosenstock ,&nbsp;Riccardo Perfetti ,&nbsp;Thomas H. Marwick ,&nbsp;Gregory D. Lewis ,&nbsp;Carolyn S.P. Lam ,&nbsp;Nasrien E. Ibrahim ,&nbsp;Justin Ezekowitz ,&nbsp;Stefano Del Prato ,&nbsp;Javed Butler ,&nbsp;James L. Januzzi","doi":"10.1016/j.jdiacomp.2025.109059","DOIUrl":"10.1016/j.jdiacomp.2025.109059","url":null,"abstract":"<div><h3>Aims</h3><div>Assess the determinants of health status and its correlation with key parameters in individuals with diabetic cardiomyopathy (DbCM).</div></div><div><h3>Methods</h3><div>In the ARISE-HF trial, the Kansas City Cardiomyopathy Questionnaire (KCCQ), cardiopulmonary exercise testing (CPET), Physical Activity Scale for the Elderly (PASE) score, echocardiographic, and laboratory assessments were performed at baseline in 691 persons with DbCM.</div></div><div><h3>Results</h3><div>Study participants with lower KCCQ-Clinical Summary Score (CSS) were predominantly women, had poorer kidney function, higher body-mass index and natriuretic peptides, and lower hemoglobin levels. Lower KCCQ-CSS scores were associated with shorter CPET duration, lower peak exercise oxygen consumption (VO₂) and lower PASE scores, but the correlations were weak (CPET duration: <em>r</em> = 0.14, 95 % CI: 0.07–0.22; peak VO₂: <em>r</em> = 0.21, 95 % CI: 0.14–0.28; PASE score: <em>r</em> = 0.19, 95 % CI: 0.11–0.26), indicating that although worse health status was linked to poorer function and activity, the strength of these relationships was limited. No meaningful associations were observed between KCCQ-CSS and echocardiographic measurements, cardiac biomarkers, or kidney function.</div></div><div><h3>Conclusion</h3><div>Health status in Stage B heart failure due to DbCM is frequently impaired. Among those with DbCM the KCCQ is only weakly correlated with the CPET parameters and PASE score implying these assessments provide unique information.</div></div><div><h3>Trial registration</h3><div>ARISE-HF, <span><span>NCT04083339</span><svg><path></path></svg></span></div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 7","pages":"Article 109059"},"PeriodicalIF":2.9,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143890961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter to the editor by Lai-Ming Kathleen Pak et al on: Identifying predictors of SGLT2 inhibitor and GLP1R agonist use in hospital among adults with diabetes.","authors":"Michael Colacci, Ashley Raudanskis, Michael Fralick","doi":"10.1016/j.jdiacomp.2025.109046","DOIUrl":"https://doi.org/10.1016/j.jdiacomp.2025.109046","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":" ","pages":"109046"},"PeriodicalIF":2.9,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 receptor agonists and MASLD in diabetes: A promising path?","authors":"Grazia Pennisi ,&nbsp;Salvatore Petta ,&nbsp;Viviana Maggio ,&nbsp;Manfredi Rizzo","doi":"10.1016/j.jdiacomp.2025.109041","DOIUrl":"10.1016/j.jdiacomp.2025.109041","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 7","pages":"Article 109041"},"PeriodicalIF":2.9,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity and its management in primary care setting","authors":"Mahmoud Ibrahim ,&nbsp;Ebtesam M. Ba-Essa ,&nbsp;Jessica A. Alvarez ,&nbsp;Jason Baker ,&nbsp;Vincenzo Bruni ,&nbsp;Avivit Cahn ,&nbsp;Antonio Ceriello ,&nbsp;Francesco Cosentino ,&nbsp;Melanie J. Davies ,&nbsp;Francesco De Domenico ,&nbsp;Robert H. Eckel ,&nbsp;Allon N. Friedman ,&nbsp;Jonathan Goldney ,&nbsp;Omer Hamtzany ,&nbsp;Scott Isaacs ,&nbsp;Sehnaz Karadeniz ,&nbsp;Richard David Leslie ,&nbsp;Ildiko Lingvay ,&nbsp;Sue McLaughlin ,&nbsp;Omar Mobarak ,&nbsp;Guillermo E. Umpierrez","doi":"10.1016/j.jdiacomp.2025.109045","DOIUrl":"10.1016/j.jdiacomp.2025.109045","url":null,"abstract":"<div><div>Obesity is a worldwide epidemic affecting adults and children, regardless of their socioeconomic status. Significant progress has been made in understanding the genetic causes contributing to obesity, shedding light on a portion of cases worldwide. In young children with severe obesity however, recessive mutations, i.e., leptin or leptin receptor deficiency should be sought. Much more has been learned about the far-reaching impact of obesity on complications, including cardiovascular disease, liver and kidney dysfunction, diabetes, inflammation, hypertension, sleep, cancer, and the eye. Preventive strategies, particularly in children, are crucial for reducing obesity rates and mitigating its long-term complications. While dietary modifications and lifestyle changes remain the cornerstone of obesity prevention or treatment, recent advancements have introduced highly effective pharmacological options complementing weight-reduction surgery.</div><div>Newer medications, like incretin-based therapies including glucagon-like peptide-1 agonists (GLP-1RA), have demonstrated remarkable efficacy in promoting weight loss, offering new insights into margining obesity-related conditions. Primary care providers, whether treating adults or children, play a pivotal role in preventing obesity, initiating treatment, and making onward referrals to specialists to assist in managing obesity and obesity-related complications.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 7","pages":"Article 109045"},"PeriodicalIF":2.9,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143881796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of circRNA in insulin resistance and its progression induced by adipose inflammation","authors":"Yifei Liu ,&nbsp;Jie Yue ,&nbsp;Yuxia Jiang ,&nbsp;Xu Tian ,&nbsp;Aihua Shu","doi":"10.1016/j.jdiacomp.2025.109042","DOIUrl":"10.1016/j.jdiacomp.2025.109042","url":null,"abstract":"<div><div>CircRNAs refer to a type of closed circular non-coding RNA without a 5′ cap or a 3′ poly (A) structure. They are largely distributed in the cytoplasm or localized in exosomes and cannot be easily degraded by RNA exonuclease activity. Their stable expression is broadly observed across eukaryotic species. Insulin resistance (IR) refers to the inability of insulin to exert its normal biological function, as manifested by the impairment of glucose utilization in peripheral tissues (e.g., muscle and fat tissues). IR is a key factor in the pathogenesis of Type 2 diabetes (T2D) and is closely associated with obesity. Recent studies have shown that certain circRNAs play critical roles in obesity-induced diabetes by regulating IR and participating in inflammatory processes. CircRNAs, with their multiple microRNA (miRNA) binding sites, act as miRNA sponges to eliminate the inhibitory actions of miRNAs and up-regulate the expression of target genes. CircRNAs play a significant role in regulating obesity-induced diabetes through their interactions with disease-related miRNAs. In the present study, we explored the biological characteristics of circRNAs and extensively discussed the role of circRNAs in the development of inflammation and IR in adipocytes, highlighting their potential as therapeutic targets for obesity-induced diabetes. Specific circRNAs (e.g., circARF3 and circ-ZNF609) have been identified as key players in modulating IR and inflammatory responses in adipose tissue. CircRNAs are emerging as important regulators of IR and inflammation in adipocytes, with significant potential for therapeutic intervention in obesity-induced diabetes. Further research is needed to elucidate the mechanisms underlying their actions and to explore strategies for targeting circRNAs in clinical applications.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 7","pages":"Article 109042"},"PeriodicalIF":2.9,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143870502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Body-weight functional exercise promotes greater and safer blood glucose reduction compared to aerobic and strength exercises in type 1 diabetics: a randomised crossover study","authors":"Pooya Soltani ,&nbsp;Fernanda Mendes Almeida ,&nbsp;Hildene Carneiro de Castro Melo ,&nbsp;Guilherme Bruno Santiago Ferreira ,&nbsp;Leiticiany Melo dos Santos ,&nbsp;Jorge Luiz de Brito Gomes","doi":"10.1016/j.jdiacomp.2025.109043","DOIUrl":"10.1016/j.jdiacomp.2025.109043","url":null,"abstract":"<div><h3>Aims</h3><div>Aerobic and strength exercises are commonly recommended for patients with type-1 diabetes (T1DM) but may not suit everyone. Body-weight functional exercise (BWFE) could offer an alternative for diabetes management. We aimed to compare blood glucose (BG), cardiovascular responses and enjoyment levels following a 30-min session of BWFE versus interval aerobic exercise (IAE) and strength exercise (STE) in patients with T1DM.</div></div><div><h3>Methods</h3><div>Ten T1DM participants (seven female) completed three randomised exercise sessions. BG, heart rate (HR), blood pressure (BP) and double product (DP) were measured before (PRE), immediately after (POST-0) and 20 min post-exercise (POST-20). Maximum and average HR were recorded, and enjoyment levels (EL) were assessed post-exercise. Statistical analysis used generalised estimated equations, with minimal detectable difference for assessing clinical significance.</div></div><div><h3>Results</h3><div>We observed clinically meaningful reductions in BG after all sessions, but only BWFE showed a statistically significant drop at POST-0 (−2.2 mmol/L) without hypoglycaemia. HR, BP and DP responses were similar across sessions. BWFE showed the highest EL and maximal HR.</div></div><div><h3>Conclusions</h3><div>BWFE effectively lowered BG safely and provided comparable cardiovascular effects to IAE and STE while being more enjoyable. These findings support incorporating functional exercises into T1DM management to encourage sustained physical activity.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 7","pages":"Article 109043"},"PeriodicalIF":2.9,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143874735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of SGLT2 inhibitors and GLP-1 receptor agonists on the triglyceride to HDL cholesterol ratio and the triglyceride-glucose index in patients with type 2 diabetes","authors":"Dimitra Voziki ,&nbsp;Georgios Dimakopoulos ,&nbsp;Ioannis Stergiou ,&nbsp;Ioanna Zografou ,&nbsp;Manfredi Rizzo ,&nbsp;Evangelos N. Liberopoulos ,&nbsp;Kalliopi Kotsa ,&nbsp;Theocharis Koufakis","doi":"10.1016/j.jdiacomp.2025.109044","DOIUrl":"10.1016/j.jdiacomp.2025.109044","url":null,"abstract":"<div><div>We analyzed the medical records of 100 patients with type 2 diabetes to evaluate the effects of new antidiabetic drugs on the TG/HDL-C ratio and the TG-glucose index. We found that GLP-1 RA treatment significantly improved both markers, while SGLT2 inhibitors led to significant reductions only in the latter.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 6","pages":"Article 109044"},"PeriodicalIF":2.9,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143848128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence to statins and development of atherosclerosis-related events. A systematic review and meta-analysis","authors":"Athanasios Basios ,&nbsp;Christina A. Chatzi ,&nbsp;Georgios Markozannes ,&nbsp;Evangelia E. Ntzani ,&nbsp;Fotios Barkas ,&nbsp;Konstantinos K. Tsilidis ,&nbsp;Manfredi Rizzo ,&nbsp;Aikaterini Kalampoki ,&nbsp;Evangelos C. Rizos","doi":"10.1016/j.jdiacomp.2025.109040","DOIUrl":"10.1016/j.jdiacomp.2025.109040","url":null,"abstract":"<div><h3>Background</h3><div>Adherence to lipid-lowering treatment (LLT) is of paramount importance for the prevention of atherosclerosis-related events (ASCVD). The threshold for someone to be adherent is ≥80 % of the total prescribed medication. We conducted a meta-analysis to assess how adherence to LLT affects the development of ASCVD.</div></div><div><h3>Methods</h3><div>We searched PubMed (up to February 2025) for randomized controlled trials, cohorts and nested case control studies that assessed adherence to LLT. We performed random effects meta-analysis with primary outcome the development of ASCVD based on the level of adherence to LLT.</div></div><div><h3>Results</h3><div>We included 66 articles corresponding to 3,345,718 individuals. All studies evaluated statins as LLT. Good vs. poor statin adherence reduced by 35 % the risk for all-cause mortality (RR:0.65; 95%CI: 0.56–0.76; I² = 98 %), 24 % for any cardiovascular (CV) event (RR:0.76; 95%CI: 0.72–0.80; I² = 90 %), 30 % for myocardial infarction (MI) (RR:0.70; 95%CI: 0.62–0.80; I² = 90 %) and 32 % for stroke (RR:0.68; 95%CI: 0.58–0.79; I² = 81 %). For participants without established ASCVD, statin adherence reduced by 32 % the risk for any CV event (RR:0.68; 95%CI: 0.46–1.00; I² = 97 %). For those with established ASCVD, statin adherence reduced by 25 % the risk for any CV event (RR:0.75; 95%CI: 0.64–0.88; I² = 64 %), 51 % for MI (RR:0.49; 95%CI: 0.32–0.73; I² = 80 %) and 50 % for stroke (RR:0.50; 95%CI: 0.26–0.97; I² = 87 %). Statin discontinuation increased by 90 % the mortality risk (RR:1.90; 95%CI: 1.33–2.71; I² = 87 %). Even good vs. intermediate adherence (40 %–79 %) decreased by 32 % the risk for any CV event (RR:0.68; 95%CI: 0.60–0.76; I² = 94 %). Sensitivity analyses including studies with different than the standard (≥80 %) threshold did not differ from the main results.</div></div><div><h3>Conclusion</h3><div>Statin adherence is of paramount importance to reduce ASCVD risk and mortality. Understanding adherence patterns or barriers and ensuring consistent adherence to LLT by tailored interventions should be a key priority in clinical practice and healthcare policies.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 8","pages":"Article 109040"},"PeriodicalIF":2.9,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144099307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to rebuttal","authors":"Bria George","doi":"10.1016/j.jdiacomp.2025.109036","DOIUrl":"10.1016/j.jdiacomp.2025.109036","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 6","pages":"Article 109036"},"PeriodicalIF":2.9,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143879098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Semaglutide, central retinal thickness and continuous glucose monitoring in persons with type 2 diabetes: A post-hoc analysis from a randomised trial","authors":"Søren Gullaksen ,&nbsp;Liv Vernstrøm ,&nbsp;Steffen Skovgaard Sørensen ,&nbsp;Kristian Løkke Funck ,&nbsp;Line Petersen ,&nbsp;Toke Bek ,&nbsp;Per Løgstrup Poulsen ,&nbsp;Esben Laugesen","doi":"10.1016/j.jdiacomp.2025.109039","DOIUrl":"10.1016/j.jdiacomp.2025.109039","url":null,"abstract":"<div><h3>Aims</h3><div>Glycemic control is important for preventing diabetic retinopathy (DR), but rapid improvements could deteriorate the disease. In some, but not all studies, semaglutide is speculated to worsen DR, but the mechanism is unknown. Central retinal thickness (CRT) is an early marker of DR. Therefore, the objective was to investigate whether increased Time in Range (TIR (3.9–10.0 mmol/L)), was associated with reduced CRT in persons treated with semaglutide.</div></div><div><h3>Methods</h3><div>Forty participants with type 2 diabetes were included in this post-hoc analysis of a 32-week randomised, placebo-controlled, partly open-label trial investigating the separate and combined effects of semaglutide and empagliflozin on target organ damage in 120 participants with type 2 diabetes. Individuals were randomised into four groups: i) semaglutide, ii) empagliflozin, iii) the combination or iv) placebo, <em>n</em> = 30 for each group). In the present study, 10 participants from each of the 4 arms participated. TIR was assessed using Continuous Glucose Measurement for 7–8 days and CRT was assessed using ocular coherence tomography.</div></div><div><h3>Results</h3><div>In the 10 individuals treated with semaglutide, CRT increased ~1 % (3.76 μm, 95%CI [−0.32; 7.85], <em>p</em> = 0.065) compared to placebo. This was attenuated with adjustment for TIR (<em>p</em> = 0.21).</div><div>Independently of the four interventions, increased TIR remained associated with increased CRT (0.07 μm, 95%CI[0.03; 0.12]μm, <em>p</em> = 0.002).</div></div><div><h3>Conclusion</h3><div>Semaglutide treatment did not impact CRT beyond what could be explained by changes in glycaemia. Across all interventions, increased TIR was associated with increases in CRT, thus supporting the link between rapid improved glycemia and DR.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 6","pages":"Article 109039"},"PeriodicalIF":2.9,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143829425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}